1. Home
  2. KALA vs ICCC Comparison

KALA vs ICCC Comparison

Compare KALA & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo KALA BIO Inc.

KALA

KALA BIO Inc.

HOLD

Current Price

$0.55

Market Cap

6.0M

Sector

Health Care

ML Signal

HOLD

Logo ImmuCell Corporation

ICCC

ImmuCell Corporation

HOLD

Current Price

$6.15

Market Cap

55.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KALA
ICCC
Founded
2009
1982
Country
United States
United States
Employees
38
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.0M
55.5M
IPO Year
2017
1987

Fundamental Metrics

Financial Performance
Metric
KALA
ICCC
Price
$0.55
$6.15
Analyst Decision
Buy
Analyst Count
3
0
Target Price
$31.50
N/A
AVG Volume (30 Days)
11.7M
34.6K
Earning Date
11-19-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.26
Revenue
N/A
$27,769,304.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$23.82
Revenue Growth
N/A
16.49
52 Week Low
$0.51
$4.28
52 Week High
$20.60
$7.60

Technical Indicators

Market Signals
Indicator
KALA
ICCC
Relative Strength Index (RSI) 36.67 58.30
Support Level $0.57 $6.01
Resistance Level $0.72 $7.12
Average True Range (ATR) 0.08 0.34
MACD 0.04 0.03
Stochastic Oscillator 16.55 38.46

Price Performance

Historical Comparison
KALA
ICCC

About KALA KALA BIO Inc.

Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.

About ICCC ImmuCell Corporation

ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.

Share on Social Networks: